ADP Receptors of Platelets and their Inhibition

Summary

ADP plays a crucial role in haemostasis and thrombosis and its receptors are potential targets for antithrombotic drugs. Two G-protein coupled P2 receptors contribute to platelet aggregation: the P2Y₁ receptor initiates aggregation through mobilisation of calcium stores, while the more recently identified P2Y₁₂ receptor coupled to adenylyl cyclase inhibition is essential for a full aggregation response to ADP and the stabilisation of aggregates. The latter is defective in certain patients with a selective congenital deficiency of aggregation to ADP. It is also the target of the antithrombotic drug clopidogrel and of ATP analogues and other compounds currently under evaluation. In addition, the P2X₁ ionotropic receptor is present in platelets but its role is not yet completely known. Studies in P2Y₁ knock-out mice and experimental thrombosis models using selective P2Y₁ antagonists have shown that the P2Y₁ receptor, like the P2Y₁₂ receptor, is a potential target for new antithrombotic drugs.

Key words

ADP - platelets - P2 receptors - pharmacology - thrombosis - antiplatelet drugs

• References

• 1 Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12: 1-117.
• 2 Gaarder A, Jonsen L, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-2.
• 3 Ollgaard E. Macroscopic studies of platelet aggregation: nature of an aggregating factor in red blood cells and platelets. Thromb Diath Haemorrh 1961; 6: 86-97.
• 4 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 27-9.
• 5 Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial point of view. Circulation 1985; 72: 741-2.
• 6 MacFarlane DE. Agonists and receptors: adenosine diphosphate. In: Platelet Responses and Metabolism. Holmsen H. ed. Boca Raton, Florida: CRC Press; 1987: 19-36.
• 7 Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1988; 59: 225-30.
• 8 Féliste R, Delebassée D, Simon MF, Chap H, Defreyn G, Vallee E, Douste-Blazy L, Maffrand JP. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 1987; 48: 403-15.
• 9 Defreyn G, Bernat A, Delebassée D, Maffrand JP. Pharmacology of ticlopidine: a review. Semin Thromb Hemost 1989; 2: 159-66.
• 10 Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: 835-56.
• 11 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
• 12 Reimers HJ. Adenine nucleotides in blood platelets. In: The Platelets: Physiology and Pharmacology. Longenecker GL. ed. Orlando: Academic Press; 1985: 85-98.
• 13 Weiss HJ. Inherited abnormalities of platelet granules and signal transduction. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, Third Edition. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. Philadelphia: J. B. Lippincott; 1994: 673-84.
• 14 Savi P, Herbert JM. Pharmacology of ticlopidine and clopidogrel. Haematologica 2000; 85: 73-7.
• 15 Humphries RG. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials. Haematologica 2000; 85: 66-72.
• 16 Zawilska KM, Born GVR, Begent NA. Effect of ADP utilizing enzymes on the arterial bleeding time in rats and rabbits. Br J Haematol 1982; 50: 317-25.
• 17 Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch II JS, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD. Targeted disruption of cd39/diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 5: 1010-7.
• 18 Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Gayle RB III, Pinsky D, Malizewski CR. Human ecto-ADPase/CD39: thromboregulation via a novel pathway. Haematologica 2000; 85: 53-7.
• 19 Cattaneo M. Hereditary defect of the platelet ADP receptor(s). Platelets 1998; 8: 161-4.
• 20 Nurden P, Gauthier B, Poujol C, Pasquet JM, Nurden AT. Congenital defects of ADP receptors on platelets. Haematologica 2000; 85: 46-52.
• 21 Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
• 22 Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 58-178.
• 23 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-65.
• 24 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-76.
• 25 Cooper DMF, Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979; 282: 517-8.
• 26 Mellwig KP, Jakobs KH. Inhibition of adenylate cyclase by ADP. Thromb Res 1980; 18: 7-17.
• 27 Sage SO, Rink TJ. Kinetic differences between thrombin induced and ADP induced calcium influx and release from internal stores in fura-2 loaded human platelets. Biochem Biophys Res Commun 1986; 136: 1124-9.
• 28 Mahaut-Smith MP, Sage SO, Rink TJ. Rapid ADP evoked currents in human platelets recorded with the nystatin permeabilized patch technique. J Biol Chem 1992; 267: 3060-5.
• 29 Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G q-deficient mice. Nature 1997; 389: 183-6.
• 30 Yang X, Sun L, Ghosh S, Rao AK. Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished pleckstrin phosphorylation: evidence for defective phospholipase C activation. Blood 1996; 88: 1676-83.
• 31 Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK. Platelet signal transduction defect with G subunit dysfunction and diminished G q in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997; 94: 8750-5.
• 32 Haslam RJ. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 1973; 6: 333-50.
• 33 Gachet C, Cazenave JP, Ohlmann P, Hilf G, Wieland T, Jakobs KH. ADP receptor induced activation of guanine nucleotide binding proteins in human platelet membranes. Eur J Biochem 1992; 207: 259-63.
• 34 Ohlmann P, Laugwitz KL, Nürnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP-receptor activates Gi₂ proteins. Biochem J 1995; 312: 775-9.
• 35 Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-88.
• 36 Kowalska MA, Ratajczack MZ, Majka M, Jin J, Kunapuli S, Brass L, Poncz M. Stromal cell-dereived factor-1 and macrophage-derived chemokine: 2 chemokines that activates platelets. Blood 2000; 96: 50-7.
• 37 Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
• 38 Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
• 39 Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75: 1081-6.
• 40 Kinlough-Rathbone RL, Packham MA, Perry DW, Mustard JF, Cattaneo M. Lack of stability of aggregates after thrombin-induced reaggregation of thrombin-degranulated platelets. Thromb Haemost 1992; 67: 453-7.
• 41 Lau LF, Pumiglia K, Côté YP, Feinstein MB. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J 1994; 303: 391-400.
• 42 Polgar J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphsphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998; 91: 549-54.
• 43 Gratacap MP, Hérault JP, Viala C, Ragab A, Savi P, Herbert JM, Chap H, Plantavid M, Payrastre B. FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood 2000; 96: 3439-46.
• 44 Nieswandt B, Bergmeier W, Eckly A, Schulte V, Ohlmann P, Cazenave JP, Zirngibl H, Offermanns S, Gachet C. Evidence for cross-talk between GPVI and Gi coupled receptors during collagen-induced platelet aggregation. Blood. 2001 In press.
• 45 Payrastre B, Gratacap MP, Trumel C, Missy K, Chap H, Gachet C, Plantavid M. ADP: an important cofactor of PI 3-kinase activation in human blood platelets. Haematologica 2000; 85: 32-6.
• 46 MacFarlane DE, Mills DC. The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood 1975; 46: 309-20.
• 47 Hourani SMO. Pharmacology of the platelet ADP receptors: agonists and antagonists. Haematologica 2000; 85: 58-65.
• 48 Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J 1986; 233: 309-19.
• 49 Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Burn-stock G, Barnard EA. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 1993; 324: 219-23.
• 50 Léon C, Vial C, Cazenave JP, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y₁ purinoceptor. Gene 1996; 171: 295-7.
• 51 Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of the human P2Y₁ purinoceptor. Biochem Biophys Res Comm 1996; 218: 783-8.
• 52 Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y₁ receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30.
• 53 Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y₁ receptor: similarities with the platelet ADP receptor. Mol Pharmacol 1998; 53: 727-33.
• 54 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y₁ receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
• 55 Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y₁ purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
• 56 Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y₁ receptor is necessary for ADP-induced platelet aggregation. Blood 1998; 92: 152-9.
• 57 Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-9.
• 58 Geiger J, Honig-Liedl Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 1998; 351: 235-46.
• 59 Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y₁-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 1998; 124: 157-64.
• 60 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y₁ receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-66.
• 61 Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 1999; 81: 111-7.
• 62 Léon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave JP, Lecchi A, Cattaneo M. The P2Y₁ receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999; 81: 775-81.
• 63 Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y₁-deficient mice. Nat Med 1999; 5: 1199-202.
• 64 Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thromboembolism in purinergic P2Y₁ receptor null mice. J Clin Invest 1999; 104: 1731-7.
• 65 MacFarlane DE, Srivastava PC, Mills DC. 2-Methylthioadenosine[beta-³²P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983; 71: 420-8.
• 66 Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
• 67 Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Laibelman A, Reynolds EE, Conley PB. 1999. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Blood 1998; 92: 303a (abstr).
• 68 Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
• 69 Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu HY, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma F. ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999. J Biol Chem 2001; 276: 8608-15.
• 70 Savi P, Laplace MCL, Herbert JM. Evidence for the existence of two different ADP binding sites on rat platelets. Thromb Res 1994; 76: 157-69.
• 71 Savi P, Laplace MCL, Maffrand JP, Herbert JM. Binding of [³H]-2 Methyl-thio-ADP to rat platelets. Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-7.
• 72 Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-44.
• 73 Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlman P, Cazenave JP, Mannucci PM. Deficiency of [³³P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxaneA2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77: 986-90.
• 74 Baurand A, Raboisson P, Freund M, Léon C, Cazenave JP, Bourguignon JJ, Gachet C. Inhibition of platelet function by administration of MRS 2179, a P2Y₁ receptor antagonist. Eur J Pharmacol 2001; 412: 213-21.
• 75 MacKenzie A, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X₁ not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-81.
• 76 Vial C, Hechler B, Léon C, Cazenave JP, Gachet C. Presence of P2X₁ purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-4.
• 77 Sun B, Li J, Okahara K, Kambayashi J. P2X₁ purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998; 273: 11544-7.
• 78 Scase TJ, Heath MF, Allen JM, Sage SO, Evans RJ. Identification of a P2X₁ purinoceptor expressed on human platelets. Biochem Biophys Res Commun 1998; 242: 525-8.
• 79 Clifford EE, Parker K, Humphreys BD, Kertesy SB, Dubyak GR. The P2X₁ receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leucocytes. Blood 1998; 91: 3172-81.
• 80 Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. Agonist action of adenosine triphosphates at the human P2Y₁ receptor. Mol Pharmacol 1998; 54: 1118-23.
• 81 Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X₁ receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-14.
• 82 Schluter H, Grobeta I, Bachmann J, Kaufmann R, van der Giet M, Tepel M, Nofer JR, Assmann G, Karas M, Jankowski J, Zidek W. Adenosine(5′) oligophospho-(5′) guanosines and guanosine(5′) oligophospho-(5′) guanosines in human platelets. J Clin Invest 1998; 101: 682-8.
• 83 Lewis CJ, Gitterman DP, Schluter H, Evans RJ. Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 2000; 129: 124-30.
• 84 Flores NA, Stavrou BM, Sheridan DJ. The effects of diadenosine poly-phosphates on the cardiovascular system. Cardiovasc Res 1999; 42: 15-26.
• 85 Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y₁ receptor. Mol Pharmacol 1996; 50: 1323-9.
• 86 Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y₁ receptors by N6-methyl 2′-deoxyadenosine 3′, 5′-bisphosphate. Br J Pharmacol 1998; 124: 1-3.
• 87 Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. A key role of the P2Y₁ receptor in tissue-factor-induced thrombin dependent acute thromboembolism. Studies in P2Y₁ knock-out mice and mice treated with a P2Y₁ antagonists. Circulation 2001; 103: 718-23.
• 88 Brown SG, King BF, Kim YC, Jang SY, Burnstock G, Jacobson KA. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev Res 2000; 49: 253-9.
• 89 Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem 2000; 43: 829-42.
• 90 Boyer JL, Adams M, Jang SY, Ravi RG, Jacobson JA, Harden TK. Development of P2Y₁ receptor antagonists. Drug Dev Res 2000; (suppl) 50: 21 (abstr).
• 91 Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA. Tomlinson. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-20.
• 92 Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. The thienopyridine ticlopidine selectively prevents the inhibition effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE₁ . Biochem Pharmacol 1990; 40: 2683-7.
• 93 Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopi-dine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE₁ activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-90.
• 94 Gachet C, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes. An effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost 1992; 68: 79-83.
• 95 Savi P, Artçanuthurry V, Bornia J, Grelac F, Maclouf J, Levy-toledano S, Herbert JM. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets. Br J Haematol 1997; 97: 185-91.
• 96 Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-11.
• 97 Mills DC, Puri R, Minniti C, Grana G, Freedmann MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-6.
• 98 Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-46.
• 99 Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannuci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
• 100 Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995; 95: 1612-22.
• 101 Lévy-Toledano S, Maclouf J, Rosa JP, Gallet C, Valles G, Nurden P, Nurden AT. Abnormal tyrosine phosphorilation linked to a defective interaction between ADP and its receptors on platelets. Thromb Haemost 1998; 80: 463-8.
• 102 Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2_CYC Receptors have a secretion defect despite normal thromboxane A₂ production and normal granule stores. Arterioscler Vasc Biol 2000; 20: E101-6.
• 103 Oury C, Lenaerts T, Peerlinck K, Vermylen J, Hoylaerts MF. Congenital deficiency of the phospholipase C coupled platelet P2Y₁ receptor leads to a mild bleeding disorder. Thromb Haemost (suppl) August. 1999 20 (abstr).
• 104 Oury C, Toth-Zsamboki E, Van Geet C, Thys C, Wei L, Nilius B, Vermylen J, Hoylaerts MF. A natural dominant negative P2X₁ receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275: 22611-4.
• 105 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
• 106 Savi P, Pflieger M, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coag Fibrinol 1996; 7: 249-52.
• 107 Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP. Role of intra-cellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999; 82: 1322-6.
• 108 Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-34.
• 109 Sage SO, Yamoah EH, Heermskerk JWM. The roles of P2X₁ and P2T_AC receptors in ADP-evoked calcium signalling in human platelets. Cell Calcium 2000; 28: 119-26.
• 110 Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y₁ and P2cyc receptors. Thromb Haemost 2000; 84: 484-91.
• 111 Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-54.
• 112 Bauer M, Retzer M, Wilde JI, Maschberger P, Essler M, Aepfelbacher M, Watson SP, Siess W. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 1999; 94: 1665-72.
• 113 Paul BZS, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signalling pathways. J Bio Chem 1999; 274: 28293-300.
• 114 Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of G q. Blood 2000; 96: 2134-9.
• 115 Wilde JI, Retzer M, Siess W, Watson SP. ADP-induced shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. Platelets 2000; 11: 286-95.
• 116 Hechler B, Zhang Y, Lenain N, Freund M, Cazenave JP, Gachet C, Ravid K. Platelet hyperreactivity due to overexpression of the P2Y₁ receptor in transgenic mice. Thromb Haemost. 2001 (abstract cited in the CDROM of abstracts of the XVIIIth Congress of the ISTH).
• 117 Jarvis GE, Humphries RG, Roberston MJ, Leff P. ADP can induce aggregation of human platelets via both P2Y₁ and P_2T receptors. Br J Pharmacol 2000; 129: 275-82.
• 118 Humbert M, Nurden P, Bihour C, Pasquet JM, Winckler J, Heilmann E, Savi P, Herbert JM, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: 1532-43.
• 119 Eckly A, Gendrault JL, Hechler B, Cazenave JP, Gachet C. Differential involvement of the P2Y₁ and P2cyc receptors in morphological changes during platelet aggregation. Thromb Haemost. 2001 (in press).
• 120 Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Prittchard CA, Evans RJ. Reduced vas deferens contraction and male infertility in mice lacking P2X₁ receptors. Nature 2000; 403: 86-9.
• 121 Takano S, Kimura J, Matsuoka I, Ono T. No requirement of P2X₁ purinoceptors for platelet aggregation. Eur J Pharmacol 1999; 372: 305-9.
• 122 Rolf MG, Brearley CA, Mahaut-Smith M. Platelet shape change evoked by selective activation of P2X₁ purinoceptors with α, β methylene ATP. Thromb Haemost 2001; 85: 303-8.
• 123 CAPRIE.. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
• 124 Freund M, Mantz F, Nicolini P, Gachet C, Mulvihill J, Meyer L, Beretz A, Cazenave JP. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Thromb Haemost 1993; 69: 515-21.
• 125 Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48.
• 126 Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis. Trans Assoc Am Physicians 1993; 106: 110-9.
• 127 Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488-93.
• 128 Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-6.
• 129 Herbert JM, Bernat A, Sainte-Marie M, Dol F, Rinaldi M. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993; 69: 268-71.
• 130 Hérault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 1999; 81: 957-60.
• 131 Humphries RG, Robertson MJ, Leff P. A novel series of P_2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-81.
• 132 Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther 2000; 295: 492-9.
• 133 Lenain N, Freund M, Léon C, Cazenave JP, Gachet C. Reduced platelet thrombus formation in arterioles of P2Y₁ receptor deficient mice. Thromb Haemost. 2001 (abstract cited in the CDROM of abstracts of the XVIIIth Congress of the ISTH).